Bilaketaren emaitzak - Patrick J. O’Hearn

  • Erakusten 1 - 4 emaitzak -- 4
Findu emaitzak
  1. 1
    Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate

    Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate nork Catherine A. Evans, Tao Liu, André Lescarbeau, Somarajan Nair, Louis Grenier, Johan A. Pradeilles, Quentin Glenadel, Thomas T. Tibbitts, Ann Rowley, Jonathan P. DiNitto, Erin Brophy, Erin O’Hearn, Janid A. Ali, David G. Winkler, Stanley I. Goldstein, Patrick J. O’Hearn, Christian M. Martin, Jennifer Hoyt, John R. Soglia, Culver Cheung, Melissa Pink, Jennifer Proctor, Vito J. Palombella, Martin Tremblay, Alfredo Castro

    Argitaratua 2016
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2

    Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2 nork Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, Jessica B. Casaletto, B. Barry Touré, Demetri T. Moustakas, Brandi M. Hudson, Roberto Valverde, Songping Zhao, Patrick J. O’Hearn, Lindsey Foster, Dina A. Sharon, Samuel E. Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Günaydin, Mary M. Mader, Alessandro A. Boezio, Thomas H. McLean, Rongfeng Chen, Yanxia Wang, David E. Shaw, James Watters, Donald A. Bergstrom

    Argitaratua 2024
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across<i>FGFR2</i>Alterations and Resistance Mutations

    RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across<i>FGFR2</i>Alterations and Resistance Mutations nork Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B. Barry Touré, Songping Zhao, Roberto Valverde, Patrick J. O’Hearn, Demetri T. Moustakas, Heike Schönherr, Nastaran Gerami-Moayed, Alexander M. Taylor, Brandi M. Hudson, Damian J. Houde, Debjani Pal, Lindsey Foster, Hakan Günaydin, Pelin Ayaz, Dina A. Sharon, Lipika Goyal, Alison M. Schram, Suneel Kamath, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Kai Yu Jen, Fabien Ricard, Beni B. Wolf, David E. Shaw, Donald A. Bergstrom, James Watters, Jessica B. Casaletto

    Argitaratua 2023
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Discovering the anticancer potential of non-oncology drugs by systematic viability profiling

    Discovering the anticancer potential of non-oncology drugs by systematic viability profiling nork Steven M. Corsello, Rohith T. Nagari, Ryan D. Spangler, Jordan Rossen, Mustafa Kocak, Jordan Bryan, Ranad Humeidi, D. D. Peck, Xiaoyun Wu, Andrew Tang, Vickie M. Wang, Samantha Bender, Evan Lemire, Rajiv Narayan, Philip Montgomery, Uri Ben‐David, Colin W. Garvie, Yejia Chen, Matthew G. Rees, Nicholas Lyons, James M. McFarland, Bang Wong, Li Wang, Nancy Dumont, Patrick J. O’Hearn, Eric Stefan, John G. Doench, Caitlin Harrington, Heidi Greulich, Matthew Meyerson, Francisca Vázquez, Aravind Subramanian, Jennifer A. Roth, Joshua A. Bittker, Jesse S. Boehm, Christopher C. Mader, Aviad Tsherniak, Todd R. Golub

    Argitaratua 2020
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: